Leads from Evolution-Tested, Target-Focused Libraries
Harnessing nature’s molecular arsenal, we engineer millions of drug-like toxin variants to develop novel therapeutic leads.
ToxinTech translates animal venom toxins into next-generation peptide therapeutics through the proprietary Designer Toxins platform. The platform applies functional genomics, combinatorial engineering, and structure-guided molecular design to generate target-focused therapeutic libraries. We fuel this discovery engine through globally curated venom biodiversity resources and unique access to rare and difficult-to-source biological samples spanning diverse venomous species.
This dual edge allows ToxinTech to bridge the gap between nature's evolutionary wisdom and state-of-the-art drug discovery pipelines. We partner with pharma innovators to generate IP-ready therapeutic leads targeting ion channels, cell-surface receptors, and enzymatic pathways.
Refined over 500 million years to rapidly disable targets, animal venom toxins are among nature’s most sophisticated molecules. Because they evolved to intercept vital life functions—including nerve signaling, circulation, and coagulation—they natively exhibit exceptional affinity, target selectivity, and structural stability. These motifs potently modulate a vast spectrum of human receptor classes, including ion channels, GPCRs, kinases, and enzymatic pathways, making them unparalleled drug discovery templates.
Clinical validation is demonstrated by approximately 20 approved toxin-derived medicines. Therapies such as captopril, lixisenatide, eptifibatide, and ziconotide are used in the treatment of cardiovascular disease, diabetes, and chronic pain. Additional toxin-based agents are advancing through clinical pipelines for autoimmune diseases and oncology, while others serve as molecular tools and active compounds in diagnostics and cosmetics.
An estimated 20 million toxins across 200,000 venomous species remain unexplored, representing one of the largest reservoirs of bioactive molecular diversity for future medicines.
Designer Toxins is a proprietary pharmacogenomic platform that harnesses 500 million years of evolutionary innovation in animal venoms to engineer custom peptide ligands for receptors with unmet therapeutic needs.
At its core, the platform explores Earth’s vast, untapped animal venom arsenal, leveraging target-focused, evolution-optimized chemical motifs. Using functional genomics, structure-guided diversification, and combinatorial engineering, the platform generates libraries containing millions of custom toxin variants for target-specific high-throughput screening. Libraries are screened to identify candidates with optimal biological activity, selectivity, and drug-like properties.
Originally developed at the University of Chicago by pharmacologist Zoltan Takacs, PhD and colleagues, the platform has evolved through significant proprietary advancements. Takacs’ research and training span Columbia University, Yale University, Rockefeller University, and the University of Chicago. It now integrates natural toxin templates with medicinal chemistry, computational sequence optimization, and structure-informed molecular design. This enables de novo discovery, optimization of “best-in-class” leads, and the creation of advanced peptidomimetics. Successes examples include production of leads in autoimmune diseases and oncology and biomarkers.
Animal toxins have evolved to modulate hundreds of receptor classes, ion channels, and physiological signaling pathways, giving the Designer Toxins platform broad applicability across major therapeutic areas.
Novel leads for receptors with unmet need.
Optimizing existing assets into "best-in-class" variants.
Defining chemical space for peptide and small molecule peptidomimetics.
Biological sampling and biobank strategy, end-to-end lifecycle, regulatory compliance.
